{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:54:43Z","timestamp":1781243683580,"version":"3.54.1"},"reference-count":28,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess mavacamten\u2019s role in hypertrophic cardiomyopathy treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to June 11, 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>English language studies describing mavacamten\u2019s mechanism of action, pharmacokinetics, drug interactions, clinical and economic outcomes, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Mavacamten reduces left ventricular outflow obstruction and New York Heart Association functional class while improving Kansas City Cardiomyopathy Questionnaire-Clinical Summary Scores in patients with obstructive hypertrophic cardiomyopathy. With an acquisition cost of $245.20 per capsule, it would cost $1.2 million for every additional quality-adjusted life year. In those with unobstructive hypertrophic cardiomyopathy, there were improvements in N-terminal probrain natriuretic peptide and high-sensitivity cardiac troponin biochemical markers. Mavacamten is a substrate for CYP2C19 and CYP3A4, and a CYP enzyme inducer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Patients with obstructive hypertrophic cardiomyopathy and an ejection fraction \u226555% have a new option if they remain symptomatic despite maximally tolerated \u03b2-blocker or non-dihydropyridine calcium channel blocker therapy. It is an alternative to disopyramide therapy, which has poor patient tolerance, or septal reduction therapies, which are invasive. However, mavacamten is not cost-effective and its role in nonobstructive hypertrophic cardiomyopathy is not well established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Mavacamten is a new option for patients with refractory obstructive hypertrophic cardiomyopathy and an ejection fraction \u226555% but its pricing makes therapy not cost-effective. Final health outcomes are not fully elucidated and additional studies are needed to determine long-term effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280221117812","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T03:16:10Z","timestamp":1660187770000},"page":"489-502","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.1177","volume":"57","author":[{"given":"Joseph D.","family":"Dalo","sequence":"first","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nissen D.","family":"Weisman","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9367-4893","authenticated-orcid":false,"given":"C. Michael","family":"White","sequence":"additional","affiliation":[{"name":"University of Connecticut School of Pharmacy, Storrs, CT, USA"},{"name":"Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"bibr1-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000937."},{"key":"bibr2-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-022-00532-x."},{"key":"bibr3-10600280221117812","unstructured":"Camzyos (mavacamten) [packageinsert]. Brisbane, CA: MyoKardia\/Bristol Myers Squibb, Co; April 2022. Accessed June 11, 2022. https:\/\/packageinserts.bms.com\/pi\/pi_camzyos.pdf."},{"key":"bibr4-10600280221117812","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3016."},{"key":"bibr5-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.064."},{"key":"bibr6-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X."},{"key":"bibr7-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052359."},{"key":"bibr8-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00763-7."},{"key":"bibr9-10600280221117812","unstructured":"Kumbhani DJ, Bhatt DL. Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy\u2014VALOR-HCM. American College of Cardiology Meeting Late Breaking Clinical Trial. April 2, 2022. Accessed June 11, 2022. https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2022\/04\/01\/02\/42\/VALOR-HCM."},{"key":"bibr10-10600280221117812","first-page":"369","volume":"28","author":"Beinfeld M","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr11-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.11.006."},{"key":"bibr12-10600280221117812","unstructured":"Ripa R, George T, Sattar Y. Physiology, cardiac muscle. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2022. Accessed May 27, 2022. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572070\/."},{"key":"bibr13-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00345.2020."},{"key":"bibr14-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202012789."},{"key":"bibr15-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00023.2020."},{"key":"bibr16-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167295."},{"key":"bibr17-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15271."},{"key":"bibr18-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1495856."},{"key":"bibr19-10600280221117812","unstructured":"PIONEER-LTE Study Methods. NCT03496168. ClinicalTrials.gov. Accessed June 9, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03496168?term=pioneer-ole&draw=2&rank=1."},{"key":"bibr20-10600280221117812","unstructured":"MAVA-LTE Study Methods. NCT03723655. ClinicalTrials.gov. Accessed June 9, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03723655?term=MAVA-LTE&draw=2&rank=1."},{"key":"bibr21-10600280221117812","unstructured":"REDWOOD-HCM Study Methods. NCT04219826. ClinicalTrials.gov. Accessed June 9, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04219826?term=REDWOOD-HCM&draw=2&rank=1."},{"key":"bibr22-10600280221117812","unstructured":"HORIZON-HCM Study Methods. NCT05414175. ClinicalTrials.gov. Accessed July 6, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05414175?term=HORIZON-HCM&draw=2&rank=1."},{"key":"bibr23-10600280221117812","unstructured":"EMBARK-HFpEF Study Methods. NCT04766892. ClinicalTrials.gov. Accessed July 6, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04766892?term=EMBARK-HFpEF&draw=2&rank=1."},{"key":"bibr24-10600280221117812","unstructured":"Reuter\u2019s News. FDA approves Bristol Myers\u2019 oral heart disease drug. April 29, 2022. Accessed May 27, 2022. https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/fda-approves-bristol-myers-heart-disease-drug-2022-04-29\/."},{"key":"bibr25-10600280221117812","unstructured":"Beinfeld M, Wasfy JH, Walton S, et al. Report at a glance: hypertrophic cardiomyopathy. ICER, Boston, MA; November 2021. Accessed June 30, 2022. https:\/\/icer.org\/wp-content\/uploads\/2021\/11\/HCM-RAAG_16NOV2021.pdf."},{"key":"bibr26-10600280221117812","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137218."},{"key":"bibr27-10600280221117812","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1664."},{"key":"bibr28-10600280221117812","unstructured":"Norpace (disopyramide) [packageinsert]. NewYork NY: Pfizer; September 2006. Accessed June 11, 2022. https:\/\/cdn.pfizer.com\/pfizercom\/products\/uspi_norpace.pdf."}],"updated-by":[{"DOI":"10.1177\/10600280221148269","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T00:00:00Z","timestamp":1671580800000}}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221117812","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280221117812","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280221117812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:17:01Z","timestamp":1777375021000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280221117812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1177\/10600280221117812"],"URL":"https:\/\/doi.org\/10.1177\/10600280221117812","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]}}}